Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek Pharmaceuticals, a private biotech. This deal will add OPTN’s approved product, Xhance (fluticasone propionate), to the latter’s commercial portfolio.
Xhance is an innovative drug-device therapy for chronic rhinosinusitis (CRS), with or without nasal polyps. Utilizing its proprietary Exhalation Delivery System, it delivers a corticosteroid directly to the site of inflammation, improving patient outcomes while potentially reducing the need for invasive or costly treatments.
The acquisition enables OptiNose to expand Xhance’s market reach, addressing long-standing challenges in adoption. Paratek’s strong commercial infrastructure will help drive awareness, particularly among primary care providers who treat most CRS patients.
Paratek’s recently expanded primary care field force, combined with OptiNose’s specialist sales expertise, positions the company to accelerate Xhance’s adoption across both ear, nose, and throat (ENT) and allergy specialists and the broader primary care market, maximizing its commercial potential.
Year to date, shares of OptiNose have rallied 37% against the industry’s 0.1% decline.
Image Source: Zacks Investment Research
Xhance was initially approved in 2017 for CRS with nasal polyps and marketed primarily to ENT and allergy specialists. In 2024, the product’s label was expanded to include CRS without nasal polyps, increasing its market potential nearly tenfold by bringing primary care providers into its prescriber base. Subsequently, OPTN’s Xhance became the only approved therapy for CRS patients regardless of nasal polyp status, reinforcing its position in a market with substantial unmet clinical needs.
This impending acquisition will also broaden Paratek’s commercial portfolio beyond its flagship antibiotic, Nuzyra (omadacycline). It will reinforce Paratek’s status as a multi-product company dedicated to developing innovative specialty therapies for primary care providers and specialists, tackling critical medical health challenges.
Nuzyra is a once-daily oral and intravenous antibiotic approved for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Notably, a significant portion of the primary care physicians currently engaged by Paratek for Nuzyra also manage patients with CRS, presenting a meaningful overlap that enhances salesforce efficiency and market reach.
Financial Consideration for OPTN’s Impending Acquisition
Under the agreement, all outstanding shares of OptiNose will be acquired by Paratek for $9 per share in cash, with the potential for an additional $5 per share in contingent value rights, depending on Xhance achieving certain specified revenue milestones. This brings the total deal value to up to $330 million.
The upfront cash payment of $9 per share represents a 50% premium over OptiNose’s closing share price on March 19, 2025.
The transaction is expected to be completed in mid-2025, subject to the fulfillment of certain customary and regulatory closing conditions.
OptiNose, Inc. Price and Consensus
OptiNose, Inc. price-consensus-chart | OptiNose, Inc. Quote
OPTN’s Zacks Rank & Stocks to Consider
OptiNose currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the sector are Gilead Sciences GILD, Dynavax Technologies Corporation DVAX and Arvinas ARVN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, Gilead Sciences’ earnings estimate for 2025 has improved from $7.80 to $7.87 per share. During the same timeframe, the estimate for earnings per share for 2026 has improved from $8.12 to $8.27. Year to date, shares of Gilead Sciences have gained 14.6%.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
In the past 30 days, estimates for Dynavax’s earnings per share have increased from 32 cents to 33 cents for 2025. During the same time, earnings per share have increased from 49 cents to 57 cents for 2026. Year to date, shares of DVAX have gained 6.7%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 30 days, estimates for Arvinas’ loss per share have narrowed from $3.73 to $3.49 for 2025. During the same time, loss per share has narrowed from $3.67 to $3.65 for 2026. Year to date, shares of ARVN have plunged 53.1%.
ARVN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.56%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
OptiNose, Inc. (OPTN) : Free Stock Analysis Report
Arvinas, Inc. (ARVN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Comments